{"url_path":"/sec/rmtg/10-k/2026/item-1","section_key":"item-1","section_title":"Item 1 **","topic":"sec","document":{"doc_type":"10-K","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1760026/0001213900-26-056841-index.html","accession_number":"0001213900-26-056841","cik":"0001760026","ticker":"RMTG","issuer_name":"Regenerative Medical Technology Group Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1760026/0001213900-26-056841-index.html","primary_entity_key":"0001760026","primary_entity_name":"Regenerative Medical Technology Group Inc."},"word_count":1846,"has_tables":true,"body_markdown":"** **\n\n**ITEM 1.**\n**BUSINESS**\n\n \n\n**Business Overview**\n\n \n\nRegenerative Medical Technology Group (RMTG),\nthrough its subsidiary, Global Stem Cells Group (GSCG), has established itself as one of the most comprehensively vertically integrated\norganizations in regenerative medicine worldwide. We combine physician education and global influence through the International Society\nfor Stem Cell Applications (ISSCA), advanced manufacturing and product innovation via Cellgenic, a premium clinical network delivering\nhigh-end patient care and generating real-world data, and a disciplined global expansion strategy. This closed-loop ecosystem enables\nus to drive demand, supply quality-controlled biologics and therapeutics, validate protocols through clinical applications, and leverage\ndigital technologies for scalable, recurring revenue and continuous innovation.\n\n \n\nOur mission is to empower physicians globally\nto deliver the transformative benefits of regenerative medicine—stem cell therapies, exosomes, peptides, and advanced combination\nprotocols—to patients seeking effective, natural alternatives to traditional surgical, palliative, or symptom-management approaches.\nIn 2026, we advanced this mission by executing a deliberate platform strategy centered on four core pillars: ISSCA’s educational\ndominance as the primary engine of physician acquisition and protocol standardization; Cellgenic’s manufacturing excellence and\nexpanding portfolio as the high-margin product engine; our evolving network of premium clinical centers as both a revenue generator and\nvalidation platform; and international market expansion as the repeatable mechanism for global scaling.\n\n \n\nWe support physicians, medical providers, and\naffiliated clinics with the latest protocols, biologics, automated processing systems, diagnostic tools, and ongoing training. Our revenue\nmodel is diversified and highly synergistic, encompassing professional training and certifications, recurring sales of Cellgenic products\n(exosomes, mesenchymal stem cells, peptides, and combination therapies), premium clinical treatments, equipment and kits, digital subscriptions,\nlicensing, partnerships, and franchise arrangements. This fully integrated structure creates significant sustainable competitive advantages,\nincluding elevated customer lifetime value, recurring revenue predictability, strong ecosystem lock-in, network effects, and proprietary\nclinical data assets that inform product development and protocol refinement.\n\n \n\n**Forecast for Fiscal Year 2026**\n\n \n\n2026 represents a pivotal year of strategic execution\nand platform maturation for RMTG and GSCG. Building on the foundational infrastructure established in prior periods, we expect to successfully\ntransition from a high-growth operator into a consolidated category leader in Regenerative Medicine. Through aggressive advancement of\nour vertically integrated model, we anticipate substantial progress across education, manufacturing, clinical delivery, digital enablement,\nand global market penetration. We anticipate that these initiatives will drive meaningful revenue acceleration, margin expansion, improved\noperational efficiencies, and strengthen competitive advantages, while reinforcing our role as the reference institution and preferred\necosystem for physicians worldwide.\n\n \n\n**ISSCA – Global Educational Dominance and Physician Network\nExpansion**\n\n \n\nISSCA solidified its position as the leading global\nauthority in regenerative medicine education. We executed a full calendar of 15 international events spanning five continents, including\nmajor conferences, hands-on certifications, specialty-focused programs, and regional symposiums. This continuous market presence enabled\nrapid penetration of emerging markets and the cultivation of a high-value, high-retention physician network. We expanded our educational\nofferings into a multi-layered ecosystem, launching scalable online certifications, advanced specialty programs in orthopedics, aesthetics,\nand longevity. In 2026 we expect to launch a new Diploma in Cell Therapy & Tissue Engineering, postgraduate-level curricula, and fellowship-style\ntraining. ISSCA is evolving from a training organization into a standard-setting academic authority, creating a powerful flywheel: physicians\nenter through education, adopt our protocols, integrate Cellgenic products and equipment, and remain engaged through continuous updates\nand support. This strategy deepens physician dependency, standardizes clinical practices globally, and positions ISSCA as the gateway\nto the broader regenerative medicine industry.\n\n \n\n**ISSCA Global Summit – Flagship Industry Event**\n\n \n\nThe 2025 ISSCA Global Summit in Cancún,\nattended by more than 470 doctors, professors, and medical professionals, served as the industry’s premier convergence point, featuring\nhigh-level scientific and clinical content, a distinguished international speaker lineup, and integrated tracks on exosomes, peptides,\nstem cells, longevity, biohacking, and AI in medicine. Far beyond a conference, the Summit functioned as a strategic asset that amplified\nbrand authority, drove high-conversion enrollment in certifications and product adoption, accelerated key opinion leader relationships,\nand generated substantial content for year-round marketing. It reinforced ISSCA’s role in defining industry trends and clinical\nstandards while acting as a force multiplier for downstream revenue across education, products, and partnerships.\n\n \n\n1\n\n \n\n**Cellgenic – Manufacturing Excellence and Product Portfolio\nExpansion**\n\n \n\nCellgenic advanced significantly with a fully\noperational, scalable manufacturing infrastructure supporting advanced exosome production, mesenchymal stem cell (MSC) manufacturing,\npeptide development, and quality-controlled biologics distribution. We broadened our portfolio to include next-generation exosome formulations,\npeptide products, and combination therapy solutions (MSC + exosomes + peptides), along with ready-to-use clinical kits and systems. Cellgenic\nmanufactures and sells regenerative medicine products that are supplied to physicians and clinics participating in ISSCA programs. This\nvertical integration introduced high-margin, recurring revenue streams through consumables, reduced reliance on third-party suppliers,\nand created strong brand loyalty and switching costs for physicians. Manufacturing consistency, controlled quality environments, and standardized\nprotocols differentiated us in a market challenged by variable-quality alternatives, enabling premium positioning and margin expansion.\nCellgenic’s growth was directly amplified by ISSCA’s international footprint, following a repeatable model of market entry\nthrough education, network building, product introduction, and distribution scaling.\n\n \n\n**Clinical Network – Premium Patient Experience and Scalable\nModel**\n\n \n\nOur Cellular Institute and affiliated clinics\nevolved into five-star regenerative medicine centers, emphasizing exceptional patient experience, expanded service lines (including biohacking,\nanti-aging, hormone therapy, aesthetic medicine, and advanced cellular therapies), and integration of AI-assisted diagnostics and standardized\nprotocols. We made substantial progress toward a replicable franchise model, including standardization of design, equipment, treatment\nprotocols, staff training, and patient frameworks. Clinics served as direct monetization channels for high-ticket procedures while functioning\nas validation platforms that generated real-world clinical data for protocol refinement, product improvement, and R&D. This feedback\nloop continuously strengthened the entire ecosystem. Preparations for franchise and joint-venture expansion positioned the clinical division\nas a scalable global network of centers of excellence, training hubs, and distribution points.\n\n \n\n**Cellular Institute and Stem Cell Center – Premium Clinical\nDelivery and Patient Acquisition Platforms**\n\n \n\nThe Cellular Institute serves as the Company’s\nflagship clinical and research facility in Cancún, Mexico, functioning as the central hub for patient care, physician training,\nproduct integration, and operational excellence. During 2025, we significantly expanded the Institute’s capabilities, transforming\nit from a specialized regenerative medicine clinic into a comprehensive, multi-disciplinary treatment center. The facility now offers\nan expanded portfolio of advanced therapeutic services, including plasmapheresis and blood-based therapies, regenerative medicine applications,\nand integrative longevity-focused treatments. We invested in state-of-the-art recovery and performance optimization infrastructure, such\nas hyperbaric oxygen therapy systems, electromagnetic field (PEMF) therapy equipment, and red/near-infrared light therapy. Clinical capabilities\nwere further strengthened with the addition of a fully equipped operating room and dedicated procedure suites for minimally invasive interventions.\n\n \n\nOn-site infrastructure now includes a dedicated\nbiologics processing laboratory, clean room environment, and distribution logistics center, enabling tight vertical integration of clinical\noperations, product validation, and supply chain activities. The incorporation of artificial intelligence-supported decision tools, wearable\npatient monitoring, and advanced data tracking systems has enhanced treatment personalization, outcomes analysis, and protocol optimization.\nThese developments position the Cellular Institute as a true center of excellence that supports high-quality clinical service delivery,\nphysician training through ISSCA, and the evaluation of emerging technologies.\n\n \n\nComplementing the Institute, the Stem Cell Center\noperates as our primary patient-facing clinical brand and service platform. It functions as the key interface for patient education, lead\ngeneration, and treatment coordination across international markets. Through targeted digital channels and educational content, the Stem\nCell Center drives awareness and acquisition for stem cell-based therapies, exosome and biologic-based treatments, regenerative protocols\nfor chronic & degenerative conditions, and anti-aging/longevity interventions.\n\n \n\nThe platform seamlessly refers patients to the\nCellular Institute and our affiliated network while promoting utilization of the Company’s proprietary Cellgenic product portfolio.\nBy standardizing messaging, protocols, and the patient experience, the Stem Cell Center reinforces brand consistency and facilitates medical\ntourism support, inquiry qualification, and coordinated treatment planning. Management believes that the continued enhancement of both\nthe Cellular Institute and the Stem Cell Center will meaningfully increase patient flow, improve conversion rates, strengthen global brand\nrecognition, and contribute to scalable, long-term revenue growth within our vertically integrated ecosystem.\n\n** **\n\n2\n\n** **\n\n**Argentina – Regulatory Stronghold and Market Control**\n\n \n\nIn 2026, Argentina emerged as a key strategic\nmarket for RMTG by aligning our operations with the country’s established regulatory framework for advanced biologics and cell therapy\nmanufacturing. This alignment enabled compliant, controlled production and nationwide commercialization of Cellgenic products, allowing\nus to establish exclusive distribution structures, standardize clinical protocols, and build a fully integrated national ecosystem combining\nISSCA education, product supply, and clinical services. The approach reduces regulatory risk, enhances credibility with physicians and\ninstitutions, supports stronger pricing discipline, and accelerates physician network growth and product adoption. Argentina now serves\nas both a concentrated revenue platform and a replicable blueprint for efficient expansion across Latin America.\n\n** **\n\n**Global Market Expansion**\n\n \n\nWe executed a structured, repeatable “land\nand expand” strategy focused on high-growth regions including Latin America (Argentina, Brazil, Mexico), the Middle East (UAE, Saudi\nArabia), Southeast Asia (Indonesia), South Asia (Pakistan), and Europe (Portugal, Spain, Italy). Leading with ISSCA education, followed\nby Cellgenic product distribution and clinical partnerships, enabled capital-efficient entry, rapid network development, and accelerated\nrevenue generation. This approach produced powerful network effects, brand globalization, and risk diversification across multiple geographies.\n\n \n\n**AI and Digital Ecosystem Integration**\n\n \n\nWe believe that a major differentiator in 2026\nwill be the successful launch and integration of the ISSCA AI Platform and ISSCA App. ISSCA AI delivers clinical decision support, protocol\nrecommendations, patient management, and workflow optimization, while the ISSCA App serves as the digital backbone for global physician\nnetworking, education access, and community engagement. These tools create a scalable digital layer across education, clinics, products,\nand data, introducing high-margin subscription revenue, network effects through data aggregation, and enhanced physician retention. The\ndigital infrastructure transitions the company toward a technology-enabled platform model with SaaS-like characteristics, improving valuation\npotential and operational efficiency.\n\n \n\n**Revenue Model Synergies and Ecosystem Economics**\n\n \n\nOur multi-layered revenue model—training\nand certifications, Cellgenic product sales, clinical treatments, equipment, licensing, partnerships, and digital subscriptions—operated\nas a self-reinforcing engine. Each physician has a lifecycle stage (acquisition through education, activation via protocols, monetization\nthrough products, expansion via advanced training, integration through clinics, and retention via digital platforms) that compounds in\nvalue. This produced predictable recurring revenue, elevated customer lifetime value, operational efficiencies, and ecosystem lock-in.\nThe result was a shift from linear, transaction-based economics to compounding, platform-driven growth with higher margins and greater\npredictability.\n\n \n\n**2026 Strategic Outlook**\n\n \n\nBuilding on the 2025 foundation of platform maturity\nand global scale, our priorities for 2026 center on further ecosystem optimization, accelerated clinical network franchising, deeper AI-driven\npersonalization and data monetization, continued product innovation (including advanced combination therapies and delivery systems), and\ntargeted expansion into additional regulated markets such as North America. We will maintain disciplined capital allocation toward manufacturing\ncapacity enhancements, R&D pipeline advancement, and strategic partnerships that reinforce our category leadership. Key performance\nindicators will focus on revenue growth, margin improvement, physician retention and lifetime value, clinical outcome metrics, digital\nplatform adoption, and facility utilization. With our vertically integrated model, recurring revenue base, proprietary data assets, and\nglobal network effects firmly established, we are positioned to deliver sustained, high-quality growth while advancing regenerative medicine\nstandards worldwide.\n\n \n\n3"}